Fidler John M, Ku Geoffrey Y, Piazza Duane, Xu Rensheng, Jin Renling, Chen Zhenqing
Pharmagenesis, Inc., Palo Alto, CA 94304, USA.
Transplantation. 2002 Aug 27;74(4):445-57. doi: 10.1097/00007890-200208270-00004.
PG27 is an active fraction purified from an extract of a Chinese medicinal plant, Tripterygium wilfordii Hook f. We tested PG27 in murine allogeneic bone marrow transplantation (BMT) and investigated the mechanism of graft-versus-host disease (GVHD) suppression.
Recipients in the C57BL/6 --> BDF1 murine BMT model received oral or intraperitoneal PG27.
Fourteen days of PG27 given orally or intraperitoneally prevented GVHD development and produced extended disease-free survival (more than 300 days) for many animals. PG490-88, a semisynthetic derivative of PG490 (triptolide, present in PG27), was also efficacious. PG27 reduced day 7 splenic allospecific cytotoxic T lymphocyte levels by more than 99% compared with vehicle-treated mice. Compared with normals, spleens from control allogeneic BMT mice displayed significantly reduced mononuclear cell content, an increased percentage of CD8+ cells, fewer CD4+ cells, and more activated ([interleukin-2 receptor+], IL-2R+) CD8+ T cells. PG27 increased mononuclear cell recovery, and significantly reduced the day-14 percentages of CD3+ and IL-2R+ cells in allogeneic BMT mice, producing results similar to those for syngeneic BMT mice. PG27 significantly increased concanavalin A-stimulated in vitro IL-4 production by day-14 splenocytes, with a 7- to 8-fold higher level than that produced by control cells.
PG27 treatment for only 14 days prevented GVHD induction and development and produced long-term survival. PG27 largely normalized splenic T lymphocyte subsets, reduced allospecific cytotoxic T lymphocyte activity, and increased IL-4 production capability. PG27 may suppress GVHD by the induction of anergy and a deviation away from a proinflammatory phenotype, which could be reflected in the increased potential for IL-4 production.
PG27是从中药植物雷公藤(Tripterygium wilfordii Hook f.)提取物中纯化得到的活性组分。我们在小鼠同种异体骨髓移植(BMT)中对PG27进行了测试,并研究了其抑制移植物抗宿主病(GVHD)的机制。
C57BL/6→BDF1小鼠BMT模型中的受体接受口服或腹腔注射PG27。
口服或腹腔注射PG27 14天可预防GVHD的发生,并使许多动物的无病生存期延长(超过300天)。PG490-88是PG490(雷公藤内酯醇,存在于PG27中)的半合成衍生物,也具有疗效。与赋形剂处理的小鼠相比,PG27使第7天脾脏同种异体特异性细胞毒性T淋巴细胞水平降低了99%以上。与正常小鼠相比,对照同种异体BMT小鼠的脾脏单核细胞含量显著降低,CD8+细胞百分比增加,CD4+细胞减少,活化的([白细胞介素-2受体+],IL-2R+)CD8+T细胞增多。PG27增加了单核细胞的恢复,并显著降低了同种异体BMT小鼠第14天CD3+和IL-2R+细胞的百分比,产生了与同基因BMT小鼠相似的结果。PG27显著增加了第14天脾细胞经刀豆蛋白A刺激后的体外IL-4产生,其水平比对照细胞高7至8倍。
仅用PG27治疗14天可预防GVHD的诱导和发展,并产生长期生存。PG27在很大程度上使脾脏T淋巴细胞亚群正常化,降低了同种异体特异性细胞毒性T淋巴细胞活性,并提高了IL-4产生能力。PG27可能通过诱导无反应性和偏离促炎表型来抑制GVHD,这可能反映在IL-4产生潜力的增加上。